Lisata Therapeutics Inc LSTA

$1.58 +0.08 (5.33%)

Valuation

Market cap
13,516,000
Revenue TTM
$170,000
Net income TTM
$-16,590,000
PE ratio
0.00
Forward PE
—
Profit margin
-9,758.82%
Debt to equity
0.00

Trading

Volume
47,800
Avg volume
356,442
Day's range
$1.49 – $1.58
Shares out
9,011,000
Stochastic %K
16%
Beta
0.94
Analysts
Hold
Price target
$4.00

Price

Company profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cance...

Show more

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. As of July 21, 2026, Lisata Therapeutics, Inc. operates as a subsidiary of Kuva Labs, Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
908 842 0100
Website
https://www.lisata.com
Address
110 Allen Road, 2nd Floor, Basking Ridge, United States

Latest news

Stocktwits

skyrockets_Inc Sep 24, 6:38 PM
$LSTA For my fellow Lisata-ians, I see $LGVN now as the new LSTA when LSTA was trading at $1.0/share. See my post in the LGVN chat but I think it's a great opportunity for those looking to slowly shift out of LSTA into another similar play. Cash strapped strategic alternative play w/ a more valuable drug than Certepetide imo.
0 replies
KP2021 Sep 24, 12:40 PM
$LSTA About MAR001/005 MAR001 is a potential first-in-class monoclonal antibody in clinical development that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower triglycerides and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower triglyceride levels, improved adipose distribution, better insulin sensitivity, and protection from cardiovascular disease and type 2 diabetes
0 replies
TwongStocks Sep 24, 12:01 PM
$LSTA Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 https://ir.lisata.com/news-releases/news-release-details/marea-therapeutics-subsidiary-lisata-therapeutics-announces Presentation details are as follows: Title: TYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Concentrations Session: LBS.05: Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction Date/Time: Monday, November 9, 2026, 8:00 a.m. CT
0 replies
ikkydiphoenix Sep 24, 11:22 AM
$LSTA the only thing i'm curios about this company is to read in next sec filings whether Kuva did or didnt make an offer.
0 replies
OrangeJoolius Sep 17, 9:40 PM
$LSTA Sold this one today for a decent profit. Not the result I wanted, but profit is profit. Was hoping for KUVA to buy this though, likely would have been better for shareholders. Still could have a nice run, but not gonna stick around to find out. GLTA!
2 replies
Toptradersam Sep 17, 7:58 PM
$TTWO $AFMD $LSTA $TURB $DTSS Dont miss! https://www.youtube.com/watch?v=MITtFQyWM8c
0 replies
skyrockets_Inc Sep 17, 7:52 PM
$LSTA Still holding 1/2 of my position in case it runs up a bit in the coming days/week but made out on good profit on other half. I think Kuva screwed around too long and screwed themselves in the process trying to lowball and mess around for too long. LSTA said "f*ck around and find out". Certepitide goes to the new combined company. According to SEC filing LSTA actually has -3m in cash after this process so the 14m valuation given to the company includes the NASDAQ listing value as well as value for Certeptitide. Marea clearly wanted the drug as part of the deal, I'm assuming this is why LSTA did not do a deal w/ Kuva first then merge the shell after. This merger was likely contingent on the drug coming along w/ it. I'm assuming the lawsuit against Kuva still stands as well.
1 replies
Biotech_Pharma_Investor Sep 17, 6:18 PM
$LSTA Not best case scenario for me. Nice assets, top institutions but no short term catalyst. Not the type of investment I am interested in the current market. Good luck to those holding May get pumped higher (or not). Kuva is screwed btw.
0 replies